Bristol-Myers Squibb Company
Combination of DR5 agonist and anti-PD-1 antagonist and methods of use
Last updated:
Abstract:
Provided are methods and compositions for treating cancer using an effective amount of a PD-1 antagonist in combination with a DR4 or DR5 agonist.
Status:
Grant
Type:
Utility
Filling date:
31 May 2018
Issue date:
31 Aug 2021